[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The University of Texas Medical Branch, Galveston\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":631},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,44,73,88,117,143,171,198,227,259,272,297,320,347,373,398,418,443,466,490,517,537,560,579,607],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053878","phase-1-nanopulse-laser-therapy-100053878",false,"NCT07520383","Nanopulse Laser Therapy","Biomarker Responsiveness of Nanopulse Laser Therapy in Treatment of Traumatic Brain Injury","Inclusion Criteria:\n\n* Adults aged 18 years or older at the time of enrollment\n* Confirmed diagnosis of moderate to severe TBI (clinical assessment and radiographic evidence)\n* Admission to the neurosurgical or neurocritical care service with anticipated need for intracranial monitoring (e.g., microdialysis, ICP probe)\n* Able to initiate treatment within 48 hours of admission\n* Informed consent obtained from patient or legally authorized representative\n\nExclusion Criteria:\n\n* Patients younger than 18 years of age\n* Known or suspected pregnancy (verified via urine pregnancy test for females of childbearing age)\n* Incarcerated individuals or prisoners\n* Patients with pre-existing implanted cranial devices (e.g., deep brain stimulators) that may interfere with NPLT\n* Patients with severe scalp injury or open wounds at intended treatment site\n* Known allergy or hypersensitivity to adhesives or device components","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to evaluate the safety and effectiveness of a novel noninvasive therapy, Nanopulse Laser Therapy (NPLT), to improve recovery following traumatic brain injury (TBI).",[27],"TBI (Traumatic Brain Injury)",[27,29,30],"Near-Infrared Laser Therapy","Neurometabolic Biomarkers","NOT_YET_RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":21},"2026-08",{"date":39,"type":21},"2027-05",{"name":41,"class":42},"The University of Texas Medical Branch, Galveston","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100541919","oasis-peer-support-for-t2dm-in-appalachia-peer-participant-100541919","NCT06336122","OASIS: Peer Support for T2DM in Appalachia (Peer Participant)","Older Adults Using Social Support to Improve Self-Care: Adaptation, Implementation, and Feasibility of Peer Support for Older Adults With T2DM in Appalachia.","OASIS","Inclusion Criteria:\n\n* Age greater than or equal to 55 years\n* Resident in Rural Kentucky\n* Positive Diagnosis of Type 2 Diabetes Mellitus\n* HbA1c greater than or equal to 7.5%\n* Passing score on cognitive assessment administered by study personnel\n* English Speaking\n\nExclusion Criteria:\n\n* Age less than 55 years\n* Not a resident of a Rural Kentucky County\n* No Type 2 Diabetes Mellitus Diagnosis\n* HbA1c under 7.5%\n* Cognitive Impairment\n* Non-english speaking","55 Years",{"count":54,"type":21},76,[56],"NA","The goal of this clinical trial is to compare the effects of peer coaching models in older adults with unmanaged type two diabetes. The main questions it aims to answer are:\n\n* Are peer coaching models effective at promoting Type 2 Diabetes Mellitus self-management?\n* If effective, which facets of the peer model are most effective? Peer coaches will undergo peer coach training.\n* Reach out to peer participants on a weekly\u002Fbiweekly time frame to discuss self-management and goal setting.\n\nRetain records of contact, topics discussed, and general notes on interactions. Researchers will compare differences in the frequency of contact, as well as how peer coaches were matched to peer participants to see if efficacy of the intervention is altered between groups.",[59],"Diabetes Mellitus, Type 2",[61,62,59],"Appalachian Region","Peer Influence","RECRUITING","2026-06-15",{"date":66,"type":35},"2026-06-17",{"date":68,"type":35},"2023-11-20",{"date":70,"type":21},"2027-03-31",{"name":41,"class":42},2,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":49,"acronym":50,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":87,"locationsCount":72},"100516370","oasis-peer-support-for-t2dm-in-appalachia-peer-coaches-100516370","NCT06003634","OASIS: Peer Support for T2DM in Appalachia (Peer Coaches)","Inclusion Criteria:\n\n* Age greater than or equal to 55 years\n* Resident in Rural Kentucky\n* Positive diagnosis of Type 2 Diabetes Mellitus\n* HbA1c less than 7.5 for peer coaches\n* Passing score on cognitive assessment administered by study personnel\n* English Speaking\n\nExclusion Criteria:\n\n* Age less than 55 years\n* Not a resident of a Rural Kentucky County\n* No Type 2 Diabetes Mellitus Diagnosis\n* Cognitive Impairment\n* Non-English Speaking",{"count":7,"type":21},[56],"The goal of this clinical trial is to compare the effects of peer coaching models in older adults with unmanaged type two diabetes. The main questions it aims to answer are:\n\n* Are peer coaching models effective at promoting Type 2 Diabetes Mellitus self-management?\n* If effective, which facets of the peer model are most effective? Peer coaches will undergo peer coach training.\n* Reach out to peer participants on a weekly\u002Fbiweekly time frame to discuss self-management and goal setting.\n* Retain records of contact, topics discussed, and general notes on interactions. Researchers will compare differences in the frequency of contact, as well as how peer coaches were matched to peer participants to see if efficacy of the intervention is altered between groups.",[59],[61,62,59],{"date":66,"type":35},{"date":68,"type":35},{"date":70,"type":21},{"name":41,"class":42},{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":17,"minAge":18,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":43},"100606680","the-metabolic-and-genetic-drivers-of-body-composition-changes-following-weight-loss-surgery-100606680","NCT07178704","The Metabolic and Genetic Drivers of Body Composition Changes Following Weight Loss Surgery","PILOT STUDY: The Metabolic and Genetic Drivers of Body Composition Changes Following Weight Loss Surgery","Inclusion Criteria (Healthy Volunteers):\n\n* Age: 30 to 50 years at time of consent\n* BMI: 20-25 kg.m-2\n* Male or Female\n* All races and ethnic backgrounds\n* Ability to speak and read English\n* Subject has provided informed consent in a manner approved by the IRB and is willing and able to comply with the trial procedures.\n\nInclusion Criteria (Bariatric Surgery Patients):\n\n* Age: 18 to 65 years at time of consent\n* BMI: 35-50 kg.m-2\n* Scheduled to undergo bariatric surgery at UTMB\n* All races and ethnic backgrounds\n* Ability to speak and read English\n* Subject has provided informed consent in a manner approved by the IRB and is willing and able to comply with the trial procedures.\n\nAdditional inclusion criteria for patients undergoing enhanced metabolic assessment:\n\n* Age: restricted to 30 to 50 years of age\n* Undergoing gastric bypass surgery\n\nExclusion Criteria (Healthy Volunteers):\n\n* Heart, vascular, or pulmonary disease\n* Uncontrolled blood pressure (systolic BP \\> 170, diastolic BP \\> 95 mmHg)\n* Impaired renal function (creatinine \\> 1.5 mg\u002Fdl)\n* Anemia (hematocrit \\\u003C 33 % or donated blood in the past 12 weeks.)\n* Diabetes mellitus or other untreated endocrine or metabolic disorder\n* Recent (5 years or less) history of cancer\n* Systemic steroids, anabolic steroids, growth hormone, or immunosuppressant use within 6 months.\n* Recent (6 months) adherence to a weight-loss or weight-gain diet, resulting in a weight change of 10% or more.\n* Body mass index \\> 25.5 kg.m-2\n* Body mass index \\\u003C 19.5 kg.m-2 or recent history (\\\u003C 12 months) of disordered eating.\n* Acute infectious disease or chronic infection.\n* Pregnancy or breast-feeding.\n* Recent (1 month) consumption of protein-based sports supplements.\n* Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation.\n* Known allergic reaction to any agent under investigation or required by the protocol, including Phenylketonuria.\n* Unable to lie still in a supine position for 10 minutes.\n* History of prior non-compliance or the presence or history of a psychiatric condition (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the subject to comply with the study procedures or follow the investigators instructions.\n* Concurrent participation in another research study.\n* Use of an investigational agent in the 30 days prior to signing informed consent.\n\nExclusion Criteria (Bariatric Surgery Patients):\n\n* Fails the medical criteria for bariatric surgery.\n* Anemia (hematocrit \\\u003C 33 % or donated blood in the past 12 weeks.)\n* Recent (5 years or less) history of cancer\n* Systemic steroids, anabolic steroids, growth hormone, or immunosuppressant use within 6 months.\n* Body mass index \\\u003C 35 or \\> 50 kg.m-2.\n* Acute infectious disease or chronic infection.\n* Pregnancy or breast-feeding.\n* Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation.\n* History of prior non-compliance that would, in the opinion of the investigator, make it difficult for the subject to comply with the study procedures or follow the investigator's instructions.\n* Concurrent participation in another research study.\n* Use of an investigational agent in the 30 days prior to signing informed consent.\n\nAdditional exclusion criteria for patients undergoing enhanced metabolic assessment:\n\n* Known allergic reaction to any agent under investigation or required by the protocol, including Phenylketonuria.\n* Unable to lie still in a supine position for 10 minutes.\n* Previous bariatric surgery or undergoing a procedure other than gastric bypass (e.g. sleeve gastrectomy).",true,"65 Years",{"count":98,"type":21},110,"OBSERVATIONAL","Weight loss surgery is very good at reducing body weight but it can also cause the loss of both muscle and strength. Some patients undergoing weight loss surgery do not achieve their weight loss goals and regain the weight they lost. When this occurs, the loss of muscle and strength combined with the regain of weight can impact the individual's quality of life and ability to remain active and mobile.\n\nThe purpose of this study is to understand the behavioral, biological, and genetic factors that influence the success of weight loss surgery and its impact on muscle mass.\n\nBariatric surgery patients participating in the trial will be monitored prior to, and for a year following weight loss surgery, with data collected about their eating habits, hand grip strength, and the loss of fat, muscle, and body weight following surgery. Some patients will be additionally invited to undergo detailed metabolic assessment, where we will measure how their body uses nutrients it consumes, the composition of their body (e.g. how much lean and fat tissue they have and where it is stored), identify the bacteria living in their gut, and determine their physical performance. In all patients a small sample of gut tissue will be collected at a routine endoscopy performed in advance of weight loss surgery to identify the expression (activity) of genes in their DNA.\n\nHealthy subjects will also be recruited to allow us to compare between healthy weight individuals and those undergoing weight loss surgery. On a single occasion, the healthy volunteers will undergo the same detailed metabolic assessment performed in patients as described above. We will not examine the bacteria living in the gut of the healthy volunteers, nor will we collect gut tissue from these individuals.",[102],"Bariatric Surgery Patients",[104,105,106,107,108],"Body composition","Sarcopenia","Weight loss surgery","Muscle function","Protein metabolism","2026-05-20",{"date":111,"type":35},"2026-05-22",{"date":113,"type":35},"2025-11-04",{"date":115,"type":21},"2027-08",{"name":41,"class":42},{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":17,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100542817","chronic-subdural-hematoma-treatment-with-embolization-versus-surgery-study-100542817","NCT06347796","Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study","CHESS","Inclusion Criteria:\n\n1. Age 40-90 years inclusively.\n2. Per CT of the head, (one of the following): Unilateral convexity CSDH measuring at least 10 mm in thickness OR Bilateral CSDH if only one side is considered for treatment (at least 10 mm in thickness) and the contralateral side is asymptomatic and \\\u003C 10 mm in thickness.\n3. CSDH at least 2\u002F3 isodense or hypodense, verified on axial CT slice used to measure the thickness of the qualifying CSDH.\n4. Qualifying baseline head CT performed within the 7 days prior to randomization.\n5. Able to undergo assigned treatment within 72 hours after randomization.\n6. Patient or legally authorized representative agrees to be randomized, and provides written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization.\n\nExclusion Criteria:\n\n1. Secondary cause apart from trauma for the qualifying SDH, such as an underlying vascular abnormality or tumor.\n2. Tentorial or interhemispheric SDH.\n3. Secondary to CSDH, MRC of 0, 1, 2, or 3 in any muscle group contralateral to the side of the CSDH 4.\n4. Pre CSDH mRS of 5 or higher.\n5. Secondary to CSDH, patient is unable to complete TUG (i.e.,TUG \\> 120 seconds, unable to walk, or tries TUG but quits in ≤ 120 seconds). Note: This criterion does not apply if the patient does not complete TUG for reason other than CSDH.\n6. Secondary to CSDH, ASR of 0, 1, or 2.\n7. Emergent surgical evacuation such as open craniotomy, burr hole drainage, or Subdural Evacuating Port System (SEPS) is required for the patient.\n8. Unable to withhold all antiplatelet agents or OACs for the first 7 days after randomization.\n9. Indication that withdrawal of care will be implemented for the qualifying SDH.\n10. Prior surgical treatment for CSDH if the surgery is less than 30 days prior to randomization.\n11. On tranexamic acid.\n12. Platelet count of \\\u003C100,000 per microliter refractory to transfusion.\n13. Coagulopathy that cannot be corrected to an INR of ≤1.5.\n14. Known contraindications to angiography.\n15. Known intolerance to occlusion procedures.\n16. Known vascular anatomy (small artery size) or blood flow (high vascular resistance peripheral to the feeding arteries) that precludes catheter placement or embolic agent (Embosphere Microspheres or CONTOUR particles) injection.\n17. Known presence of collateral vessel pathways potentially endangering normal territories or cranial nerves during embolization.\n18. Known large diameter arteriovenous shunt, i.e., where the blood does not pass through an arterial\u002Fcapillary\u002Fvenous transition but directly from an artery to a vein or presence of patent extra-to-intracranial anastomoses (where study embolization devices could pass directly into the internal carotid artery, vertebral artery, or intracranial vasculature) that cannot be addressed with coil embolization.\n19. Patient has a known active systemic infection or sepsis.\n20. Patient is pregnant, planning to become pregnant, or lactating.\n21. Life expectancy of less than 6 months due to comorbid terminal conditions.\n22. Concurrent participation in another research protocol for investigation of an experimental therapy.\n23. Known or suspected to not be able to comply with the study protocol.\n24. For unilateral CSDH, no measurable deficit secondary to the CSDH on the Timed Up and Go \\[TUG\\], Aphasia Severity Rating \\[ASR\\], or MRC. At baseline, a measurable deficit on the TUG is defined as: time ≥10 seconds. At baseline, a measurable deficit on the ASR is defined as: a score ≤4. At baseline, a measurable deficit on the MRC is defined as: a score \\\u003C 5 in any muscle group contralateral to the site of the CSDH.\n25. For bilateral CSDH, no measurable deficit secondary to the treatment-eligible CSDH on the ASR or MRC. At baseline, a measurable deficit on the ASR is defined as: a score ≤4. At baseline, a measurable deficit on the MRC is defined as: a score \\\u003C 5 in any muscle group contralateral to the treatment-eligibile CSDH side.","40 Years","90 Years",{"count":127,"type":21},520,[56],"The goal of this clinical trial is to test in moderately symptomatic chronic subdural hematoma (CSDH) patients if middle meningeal artery embolization (MMAE) can be used as an alternative to conventional open surgery. The main questions it aims to answer are:\n\n* Compared to open conventional surgery, does MMAE reduce the need for rescue surgery or deaths?\n* What is the safety of MMAE and conventional open surgery in these patients?\n\nParticipants will be asked to:\n\n* Share their medical history and undergo physical examinations\n* Have blood drawn\n* Have CT scans of the head\n* Answer questionnaires\n* Undergo MMAE or conventional open surgery\n* Provide information about possible adverse events Researchers will compare participants in the MMAE group with those in the conventional open surgery group to see if there is a reduced need for rescue surgery or deaths and evaluate safety.",[131],"Chronic Subdural Hematoma",[133,134],"chronic subdural hematoma (CSDH)","middle meningeal artery embolization (MMAE)","2026-05-19",{"date":111,"type":35},{"date":138,"type":35},"2024-11-01",{"date":140,"type":21},"2029-02",{"name":41,"class":42},31,{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":12,"sex":150,"minAge":151,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":43},"100577576","phase-2-sildenafil-to-prevent-and-reduce-cancer-related-cognitive-impairment-100577576","NCT06800092","Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment","SPARC","Inclusion Criteria:\n\n* Female\n* Ages 30 - 50 years\n* Self-reported menses occurrence within past 12 months\n* Diagnosis of ER+\u002FHER2- breast cancer\n* Willing and able to comply with study procedures\n* Willing and able to provide consent\n\nExclusion Criteria:\n\n* Untreated thyroid disorder\n* Untreated diabetes\n* BMI \\>30\n* Current treatment with metformin\n* Diagnosed neuromuscular disease\n* Diagnosed neurovascular disease\n* Prior history of cognitive impairment\n* Prior history of chemotherapy treatment\n* HIV, Hepatitis B or Hepatitis C\n* Systolic blood pressure \\\u003C90 or \\>170, diastolic blood pressure \\\u003C50 or \\>110 after repeated evaluation with proper cuff. This range is the acceptable range stated in the prescribing information for sildenafil (\\>90\u002F50 and \\\u003C170\u002F110)\n* Use of alpha blockers in the past 2 weeks\n* Use of PDE5 inhibitors in the past 2 weeks\n* Use of nitrates\n* Subjects with MRI incompatible devices\n* Subjects with severe claustrophobia\n* Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation","FEMALE","30 Years","50 Years",{"count":20,"type":21},[155,156],"PHASE2","PHASE3","This study is examining the effects of standard of care cancer treatment as well as a medication called Sildenafil, on the cancer associated fatigue, cognition and the gut microbiome.",[159],"Cancer",[161,162],"Fatigue","Brain Fog","2026-05-08",{"date":165,"type":35},"2026-05-11",{"date":167,"type":21},"2027-06-15",{"date":169,"type":21},"2030-06-01",{"name":41,"class":42},{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":186,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":43},"100624989","feasibility-and-adherence-to-a-technology-assisted-home-based-strength-training-program-in-adults-with-type-2-diabetes-mellitus-and-mild-cognitive-impairment-100624989","NCT07416799","Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment","Inclusion Criteria:\n\n1. Age: 55-80 years\n2. Diabetes: Diagnosed T2DM with ≥5 years duration\n3. Cognitive Status: Mild cognitive impairment as defined by Petersen criteria and confirmed by Montreal Cognitive Assessment (MoCA) scores of 18-25\n4. Medication Stability: Stable medication regimen for at least 3 months\n5. Physical Capability: Physically capable of participating in moderate-intensity exercise (physician clearance required)\n6. Support System: Having a caregiver or support person willing to assist with technology use if needed\n\nExclusion Criteria:\n\n1. Diagnosis of movement disorders such as multiple sclerosis, parkinson's disease\n2. Diagnosis of Alzheimer's disease,\n3. Current diagnosis of severe depression, major psychiatric conditions such as bipolar disorder, psychosis, schizophrenia, or alcoholism that could affect the ability to understand and\u002For cooperate fully with the protocol.\n4. Significant cerebral vascular disease\n5. Concomitant medications with significant cholinergic or anticholinergic effects or adverse effects on cognition, including antipsychotics, tricyclic antidepressants, anticonvulsants, sedative\u002Fhypnotics, anxiolytics, glucocorticoids (chronic or frequent intermittent),\n6. Visual\u002Fhearing impairment that would significantly impact the ability to participate in psychometric testing.\n7. Significant medical illness or organ failure, including hepatic or renal failure, unstable cardiac disease,\n8. Untreated B12 deficiency or hypothyroidism (stable treatment for at least 3 months is allowable).\n9. Uncontrolled hypertension: over 160 mmHg systolic or 100 mmHg diastolic (stable treatment is allowable).\n10. Stage 5 renal impairment (GFR less than 15 or dialysis).\n11. Participation in another clinical trial.\n12. Prisoners.\n13. Exercise Contraindications: Any condition that would make moderate-intensity exercise unsafe such as a history of severe aortic stenosis, poorly controlled hypertension, angina, or syncope.\n14. Lack of Support: No available caregiver or support person for technology assistance","80 Years",{"count":179,"type":21},20,[56],"This is a single-arm feasibility study employing a pre-post design with a 12-week intervention period. The study utilizes a telehealth-assisted home-based resistance exercise program, with a structured progression from supervised to unsupervised sessions over 12 weeks.",[183,184,185],"Type2diabetes","Mild Cognitive Impairment","Age-related Cognitive Decline",[187,188,189,190],"Home-Based exercise","Type 2 Diabetes Mellitus (T2DM)","Mild cognitive impairment (MCI)","Ages 55-80","2026-05-07",{"date":165,"type":35},{"date":194,"type":35},"2026-04-14",{"date":196,"type":21},"2027-03",{"name":41,"class":42},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":215,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":43},"100635483","vibratory-anesthesia-on-pain-following-corticosteroid-injections-100635483","NCT07553273","Vibratory Anesthesia on Pain Following Corticosteroid Injections","The Effect of Vibratory Anesthesia on Patient Pain Perception in Corticosteroid Injections of the Upper Extremity","Inclusion Criteria:\n\n* Any patient of the Principal Investigator who has clinically diagnosed bilateral arthritis, tendinopathy, arthropathy, or compression neuropathy of the hand, wrist, or elbow where treatment with corticosteroid injection is indicated.\n* Participants who voluntarily consent to participate in the study and sign consent forms.\n* Participants who complete all numeric pain rating scales\n* Patients aged ≥ 18 years old\n\nExclusion Criteria:\n\n* Participants who opt out of the study or withdraw consent\n* Participants who are determined to be without capacity to consent to study participation or injection procedure by principal investigator\n* Participants with inability to complete numeric pain rating scales\n* Participants with known allergies to triamcinolone acetonide, lidocaine, or bupivicaine\n* Participants without clinically diagnosed bilateral arthritis, tendinopathy, arthropathy, or compression neuropathy of the hand, wrist, or elbow.\n* Participants where treatment with corticosteroid injection is not indicated bilaterally.\n* Patients ≤ 18 years old",{"count":206,"type":21},165,[56],"This research study aims to evaluate injectional pain at the site of needle insertion for corticosteroid injections (CSI) of the upper extremity depending on different modes of anesthetics. Each individual's perception of pain upon receiving a CSI with two out of three modes of anesthesia (control\u002Fno anesthesia, vibrational anesthesia, vapo-coolant anesthesia) will be utilized to compare these variables and determine the method that is associated with the least pain.",[210,211,212,213,214],"Bilateral Arthritis of Wrist","Tendinopathy","Arthropathy","Compression Neuropathy","Bilateral Arthritis of Hands",[216,217,218],"Pain in Hand","Pain in Elbow","Pain in Wrist","2026-04-27",{"date":221,"type":35},"2026-05-04",{"date":223,"type":21},"2026-04",{"date":225,"type":21},"2027-04",{"name":41,"class":42},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":4},"100634347","testing-a-diabetes-care-program-in-rural-and-low-income-clinics-100634347","NCT07538505","Testing a Diabetes Care Program in Rural and Low-Income Clinics","Implementing a Diabetes Intervention in Rural and Low-Income Clinics: A Feasibility Study","Inclusion Criteria:\n\n* Self-identified Hispanic Ethnicity\n* Spanish-speaking\n* Type 2 diabetes diagnosis, .g., physician documented diagnosis, HbA1c at least 6.5, treatment with a glucose-lowering agent\n\nExclusion Criteria:\n\n* Condition known to alter HbA1c levels, e.g., recent transfusion, systemic steroids\n* Severe mental illness or cognitive impairment that would preclude participation in group activities\n* Pregnancy during the intervention period\n* Type 1 diabetes mellitus",{"count":235,"type":21},200,[56],"The goal of this study is to evaluate a Community Health Worker (CHW) program for people living with diabetes in rural areas or locations that are remote from the research team.\n\nThe study aims to answer the following questions:\n\n1. Does the CHW program improve diabetes-related health outcomes, such as blood sugar control?\n2. What is the sustainability of the program?\n3. Is the program feasible and acceptable?\n\nParticipants will be invited to attend monthly diabetes education classes led by CHWs and receive weekly mobile health check-ins from CHWs for coaching and to help coordinate care with their clinic team.",[239],"Type 2 Diabetes Mellitus",[241,242,243,244,245,246,247,248,249,250],"Community health workers","Type 2 diabetes mellitus","Rural","Hispanic","telehealth","mentor","low-income","implementation","education","access to care","2026-04-13",{"date":253,"type":35},"2026-04-20",{"date":255,"type":21},"2026-06",{"date":257,"type":21},"2031-12-31",{"name":41,"class":42},{"id":260,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":25,"conditions":263,"keywords":264,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":271,"locationsCount":43},"100632953",{"count":20,"type":21},[24],[27],[27,29,30],"2026-04-02",{"date":267,"type":35},"2026-04-09",{"date":269,"type":21},"2026-05",{"date":39,"type":21},{"name":41,"class":42},{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":95,"sex":17,"minAge":279,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":43},"100599690","optimizing-gait-symmetry-after-stroke-using-mechanical-constraints-and-sensory-feedback-100599690","NCT07087769","Optimizing Gait Symmetry After Stroke Using Mechanical Constraints and Sensory Feedback","Optimizing Post-Stroke Gait Symmetry: Integrating Mechanical Constraints and Sensory Feedback to Enhance Paretic Leg Propulsion","Inclusion Criteria:\n\nAged 20 years or older\n\nFor stroke group: clinical diagnosis of stroke at least 1 month prior to participation\n\nAbility to walk at least 10 meters with or without assistive devices\n\nFor healthy group: able to walk independently without assistive devices\n\nExclusion Criteria:\n\nLife expectancy less than one year\n\nComatose or unable to follow three-step commands\n\nAmputation of any lower limb\n\nPoorly controlled diabetes (e.g., foot ulceration)\n\nBlindness\n\nProgressive neurological disease\n\nMedically unstable condition\n\nSignificant musculoskeletal impairments affecting gait\n\nCongestive heart failure or unstable angina\n\nPeripheral vascular disease\n\nSevere neuropsychiatric conditions (e.g., dementia, cognitive deficits, severe depression)","20 Years",{"count":20,"type":21},[56],"This single-session study aims to evaluate a novel gait training protocol that integrates mechanical constraints and sensory feedback to enhance paretic leg propulsion in individuals post-stroke. The study will include 15 individuals who have experienced a stroke and 15 healthy adults, each aged 20 years or older. Participants will walk on both tied-belt and split-belt treadmills under various training conditions, including backward-directed resistance (applied at the pelvis, ankle, or both) and real-time sensory feedback (visual, auditory, or combined). These interventions will be applied individually and in combination to identify the most effective environment for promoting symmetrical gait patterns. Each session will last approximately two hours. The equipment used is non-invasive, and the risk to participants is minimal.",[284,285,286,287,288],"Stroke","Split-belt Treadmill","Resistance Exercise","Feedback","Gait Training","2026-03-31",{"date":291,"type":35},"2026-04-01",{"date":293,"type":35},"2025-07-25",{"date":295,"type":21},"2026-12-01",{"name":41,"class":42},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":95,"sex":17,"minAge":279,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":310,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":317,"leadSponsor":319,"locationsCount":43},"100599688","virtual-reality-integrated-propulsion-feedback-for-stroke-rehab-100599688","NCT07087743","Virtual Reality-Integrated Propulsion Feedback for Stroke Rehab","Virtual Reality-Integrated Limb Propulsion Visual Feedback System for End-Effector Robot-Assisted Stroke Rehabilitation","Inclusion Criteria:\n\n* Adults aged 20 years or older.\n* For post-stroke participants:\n* Diagnosis of stroke at least 1 month prior to participation.\n* Able to walk at least 10 meters with or without assistive devices.\n\nFor healthy participants:\n\n° Must walk independently without assistive devices.\n\nExclusion Criteria:\n\n* Individuals with a life expectancy of less than one year.\n* Comatose individuals.\n* Individuals unable to follow three-step commands.\n* Individuals with lower limb amputation.\n* Individuals with poorly controlled diabetes (e.g., foot ulceration).\n* Individuals with legal blindness.\n* Individuals with progressive neurological conditions.\n* Medically unstable individuals.\n* Individuals with significant musculoskeletal impairments.\n* Individuals with congestive heart failure or unstable angina.\n* Individuals with peripheral vascular disease.\n* Individuals with severe neuropsychiatric disorders (e.g., dementia, cognitive deficits, or severe depression).",{"count":20,"type":21},[56],"This study evaluates a novel Virtual Reality (VR)-integrated visual feedback system designed to enhance limb propulsion during robot-assisted gait rehabilitation in individuals post-stroke. In collaboration with CUREXO, a rehabilitation robotics company, the system is embedded within the Morning Walk® end-effector robot and provides real-time visual feedback to facilitate symmetrical use of the paretic and non-paretic limbs. The goal is to address gait asymmetry commonly observed in hemiparetic stroke survivors by promoting improved paretic leg propulsion, which is a key contributor to forward movement during walking.\n\nA total of 30 participants (15 stroke, 15 healthy controls) aged 20 years or older will undergo single-session gait training using the VR-robot system. Participants will be assessed using spatiotemporal gait parameters, muscle activity, foot pressure, and vertical ground reaction forces. Additional safety measures-including a saddle-type weight support and real-time heart rate monitoring via smartwatch-are implemented to ensure a safe and controlled training environment. This study aims to test the feasibility and effectiveness of this VR-based system in improving gait symmetry and functional walking capacity in people recovering from stroke.",[284,308,309],"Robot Assisted Gait Training","Virtual Reality",[311,312,313,309,314],"Propulsion Feedback","Gait Rehabilitation","Paretic Leg","End-Effector Robot",{"date":291,"type":35},{"date":293,"type":35},{"date":318,"type":21},"2026-12-30",{"name":41,"class":42},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":95,"sex":17,"minAge":152,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":22,"phases":329,"briefSummary":330,"conditions":331,"keywords":335,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":43},"100617047","feasibility-of-a-smartphone-application-intervention-in-community-settings-a-pretest-posttest-pilot-study-100617047","NCT07313540","Feasibility of A Smartphone Application Intervention in Community Settings: A Pretest-Posttest Pilot Study","Inclusion Criteria:\n\n1. Individuals aged 50+ who has a primary source of assistance (no age limitation for the caregiver)\n2. Both care recipient and caregiver can participate in the study for six weeks in total,\n3. Both care recipient and caregiver can read, listen, write, and speak English\n4. Both care recipient and caregiver have a personal smartphone.\n\nExclusion Criteria:\n\n1. People who are diagnosed with any middle to severe cognitive symptoms (dementia or Alzheimer's Disease) or any psychiatric disease (depression, bipolar, PTSD, Schizophrenia, anxiety disorders, eating disorders)\n2. People who are at hospice care\n3. People who plan to move out of the current area in one year, and (4) people younger than 50 (but no age limitation for caregivers)","100 Years",{"count":328,"type":21},40,[56],"The objective of this project is to test the feasibility of using a smartphone app in a community setting through collaborating with community-based organizations. The app is called utmbHealthyBrain and it has three activities: (1) drawing, (2) Tai-Chi and meditation, and (3) prayer reading. It also has a \"share\" function to enable users to interact with their family and friend. These activities can be translated to humans' well-beings such as a more stable emotion, more muscle movement, and better social engagement. This app does not collect any personal data and users are not required to register an account either. The overall study period is 6 weeks including one introduction session (week 1), four weeks of intervention (week 2 to 5), and final feedback session (week 6).",[332,333,334],"Aging","Dementia","Cognitive Decline",[336,337,338],"Smarthphone","Tai-Chi","Meditation","2026-03-25",{"date":341,"type":35},"2026-03-27",{"date":343,"type":21},"2026-10",{"date":345,"type":21},"2027-10",{"name":41,"class":42},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":43},"100609891","phase-2-tirzepatide-to-slow-biological-aging-100609891","NCT07220473","Tirzepatide to Slow Biological Aging","The Moody Longevity Trial: Tirzepatide to Slow Biological Aging","Inclusion Criteria:\n\n1. Age 55-70 years\n2. BMI ≥ 30 kg\u002Fm² or ≥ 27 kg\u002Fm² if also with ≥ 1 weight-related comorbidity\n3. If taking anti-inflammatory or blood-pressure-\u002Flipid-\u002Fglucose-lowering medications, no change in dose for ≥12 weeks prior to entry and no plans to dose escalate for the study duration\n4. Willing and able to provide written informed consent and undergo all required study procedures\n\nExclusion Criteria:\n\n1. BMI \\>35 kg\u002Fm²\n2. Uncontrolled or end-stage, comorbid, cardiometabolic disease, in the opinion of the site investigator\n3. Significant neurocognitive impairment, in the opinion of the site investigator\n4. Current or planned use of medications for the treatment of obesity, or medications likely to cause significant changes in weight, during the study period (see prohibited medications, section 6.0)\n5. Use of insulin\n6. Plans to newly engage in formal, intensive physical activity or diet (such as ketogenic or very low carbohydrate) programs during the study period\n7. Active eating disorder\n8. Use of human growth hormone, tesamorelin, supraphysiologic testosterone or estradiol (stable doses for contraception, hypogonadism or other indications for exogenous sex steroid replacement therapy permitted) or anabolic steroids \\\u003C12 W prior to entry, unless on a stable dose for \\>24 W prior to entry, or plans to start any of these medications while on study\n9. Active, severe delayed gastric emptying\n10. Prior bariatric surgery or major gastric surgery or plans for weight reduction surgery while on study\n11. Known diabetic retinopathy\n12. Personal or first-degree relative history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2\n13. Untreated, poorly controlled or previously undiagnosed thyroid disease\n14. History of chronic pancreatitis\n15. History of suicidal attempts or active suicidal ideation, in the opinion of the site investigator\n16. Known allergy\u002Fsensitivity to GLP-1RA or GIPRA\n17. Use or planned use of any immunomodulatory therapy or investigational therapy during the study period or use of an investigational therapy within 30 days of entry\n18. Any other medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation.\n19. Pregnancy, nursing or plans for either during the study period","70 Years",{"count":356,"type":21},90,[155],"This pilot clinical study aims to investigate the potential effects of tirzepatide on biological aging in older adults. In this novel study, 90 adults aged 55-70 years with an indication for tirzepatide weight-loss therapy will be randomized to receive either tirzepatide 2.5 mg subcutaneously (SC) weekly or no drug for 24 weeks, followed by 12 weeks off the drug. Since tirzepatide is already recognized as a highly effective weight-loss agent in this population, the primary focus will not be on measuring weight loss. Instead, the study will document the effects of tirzepatide on markers of aging, physical function, and overall health.",[332,360],"LONGEVITY 1",[362,363,364],"DNA Methylation","Biological Clock Deceleration","GLP-1 Agonist","2026-03-23",{"date":367,"type":35},"2026-03-24",{"date":369,"type":35},"2026-02-27",{"date":371,"type":21},"2028-01",{"name":41,"class":42},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":95,"sex":17,"minAge":18,"maxAge":96,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":43},"100601585","pain-intervention-with-needling-pilot-of-integrated-neuromodulation-techniques-100601585","NCT07112404","Pain Intervention With Needling: Pilot Of Integrated Neuromodulation Techniques","PINPOINT Study: Pain Intervention With Needling: Pilot Of Integrated Neuromodulation Techniques","PINPOINT","Inclusion Criteria:\n\n* Both males and females between the ages of 18 and 65 will be included in this study.\n\nPhase 1 Inclusion criteria\n\n\\- Healthy adults who report no pain for more than 1 day in the past 3 months in their lumbar region. Lumbar region will include posterior lumber musculature, lumbar spine, sacroiliac pain, or superior gluteal area pain.\n\nPhase 2 Inclusion criteria\n\n* Adults experiencing chronic low back pain. Chronic low back pain will be identified as having pain the lumbar region for at least 3 months. The pain may be constant or episodic in nature.\n* Participants will be included if they experience pain at least 75% of the days in the past 3 months. All pain levels will be included. Lumbar region will include posterior lumber musculature, lumbar spine, sacroiliac pain, or superior gluteal area pain.\n\nExclusion Criteria:\n\n* Individuals who are currently seeking any form of medical treatment for lumbar conditions beyond routine physician follow-up appointments in order to avoid confounding variables, regardless of pain-free status. These may include, but are not limited to, seeking treatment from a chiropractor, acupuncturist, or massage therapist or medical procedures such as injections into the lumbar region for pain.\n* Additionally, those with previous lumbar surgeries or those with previous major injuries to the lumbar spine that may have resulted in structural abnormalities that may compromise needle placement will be excluded. If surgical procedures did not alter structural alignment, then it will be allowed. For example, an approved procedure may include discectomy or nerve ablation, while a not approved procedure would include a lumbar fusion or scoliosis rod placement.\n* Additionally, if a person is experiencing radicular symptoms from a back injury, despite not feeling the symptoms in the lumbar region, will not be considered. Radicular symptoms will be defined as those present past the knee and\u002For electrical in nature. Individuals with neurological conditions or those who need the services of another due to cognitive deficits will not be considered for this study.\n* Furthermore, as this study relies on an intact sensory system, participants with conditions that may affect sensory processing (e.g., peripheral neuropathy, skin conditions, or circulatory disorders) will be excluded through careful screening.\n\nAdditional exclusion criteria\n\n* Will include the following conditions identified as contraindications for dry needling: those with impaired sensitivity, taking anticoagulants, a compromised immune system, a local or systemic infection, an active tumor, history of lymph node removal, history of autoimmune disease, allergy to metals such as nickel or chromium, history of cosmetic procedures in the area, pregnant individuals, or osteoporosis.\n* Non-English-speaking subjects will be excluded from the study due to the need to understand any communication while dry-needling procedures are taking place.",{"count":382,"type":21},42,[56],"The study's purpose is to determine the effects of three different dry needling sessions on pain and quality of life for those with chronic low back pain. Dry needling is a therapeutic procedure in which a very thin, monofilament needle is inserted through the skin to reach a target tissue like a muscle to help reduce pain, improve muscle activation, and increase blood flow. Dry needling has also been shown to improve nervous system function.",[386,387,388,389],"Pain","Back Pain","Lower Back Pain","Quality of Life","2026-03-11",{"date":392,"type":35},"2026-03-16",{"date":394,"type":35},"2025-10-23",{"date":396,"type":21},"2027-09",{"name":41,"class":42},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":43},"100528536","impact-of-a-telerehabilitation-program-with-technology-enhancement-on-post-burn-recovery-100528536","NCT06162052","Impact of a Telerehabilitation Program With Technology Enhancement on Post-burn Recovery","Inclusion Criteria:\n\n* Adults: ≥18 to ≤79 years of age\n* Not participating in another interventional trial\n* Admitted to the Blocker Burn Unit for treatment of initial burn\n* Subject is able and willing to follow the protocol requirements\n* Burn wound \u002F scar \u002F contracture occurring across at least one joint.\n* Has regular access to smart phone, tablet, or computer with internet access.\n\nExclusion Criteria:\n\n* Any medical condition that, in the opinion of the investigator or physician, would place the subject at increased risk for participation.\n* Concurrent participation on another interventional clinical trial\n* History of prior non-compliance or the presence or history of psychiatric condition (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the subject to comply with the study procedures or follow the investigators instructions.\n* Patients without internet access.","79 Years",{"count":20,"type":21},[56],"The purpose of this study is to examine the effect of participating in a tele-rehabilitation program after a burn.",[409],"Burns","2026-03-04",{"date":412,"type":35},"2026-03-06",{"date":414,"type":35},"2024-04-02",{"date":416,"type":21},"2027-12",{"name":41,"class":42},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":150,"minAge":425,"maxAge":96,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":428,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":43},"100618922","improving-sleep-in-midlife-women-100618922","NCT07337915","Improving Sleep In Midlife Women","Improving Sleep in Midlife Women","Inclusion Criteria:\n\n* All races and ethnic backgrounds\n* Between the ages of 45-65 years old\n* Women who meet STRAW staging criteria for late peri-menopause (STRAW score of -1) defined as interval of amenorrhea of 60 days OR meet STRAW staging criteria for early post-menopause (STRAW score of +1a, +1b or +1c) defined as \\>12 months since last menstrual period\n* History of poor sleep quality (Pittsburgh Sleep Quality Index score \\> 5)\n* Able and willing to provide informed consent\n* Access to an electronic device with teleconferencing capabilities (Teams, etc)\n* Willing to consume study intervention\n* Fluent (able to read and write) in English\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Recent (within the last 3 months) or current use of any prescription or over the counter medications that may impact sleep quality:\n\n  1. including, systemic steroids, anabolic steroids, growth hormone, immunosuppressants, psychotherapy)\n  2. recent (within the last 3 months) change in antidepressant medication useage or dosage\n* Untreated comorbid sleep disorders that are no known to be responsive to the behavioral interventions: These sleep disorders include but are not limited to narcolepsy, circadian rhythm disorder\u002Fshift work, restless leg syndrome, periodic leg movement disorder, obstructive sleep apnea.\n* Evidence of recent severe mental health disorders (e.g., suicide attempt or psychiatric hospitalization in past 3 years) that would, in the opinion of the investigator, affect sleep and\u002For make it difficult for the participant to the investigators instructions.\n* Recent (within past 3 years) treated cancer other than basal cell carcinoma\n* Current adherence to a weight-loss or weight-gain diet or use of GLP-1 RA medications\n* Active or recent (within the past 12 months) alcohol or substance use disorder\n* Allergy to study intervention (tree nuts)\n* Any other condition or event considered exclusionary by study PI","45 Years",{"count":427,"type":21},72,[56],"This study purpose of this study to see how consuming pistachios and completing a health intervention session a study therapist may improve sleep health in midlife women with poor sleep. Participants in this study will be asked to consume a study snack for about one month, complete a health education session with a study therapist and record information about their sleep. At baseline and after the intervention we will collect information about sleep, alertness, body composition, and blood lipids.",[431],"Poor Sleep Quality",[433,434,435],"Midlife women","Sleep","Insomnia",{"date":437,"type":35},"2026-03-03",{"date":439,"type":35},"2026-02-16",{"date":441,"type":21},"2027-08-31",{"name":41,"class":42},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":95,"sex":17,"minAge":18,"maxAge":177,"enrollmentInfo":449,"targetDuration":4,"studyType":22,"phases":451,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":43},"100608571","phase-4-risk-of-acute-complications-with-rocuronium-vs-cisatracurium-in-patients-with-chronic-kidney-disease-100608571","NCT07203287","Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* The subject is able and willing to provide and sign informed consent\n* The subject must be between 18 and 80 years of age\n* The subject should have chronic kidney disease as defined by glomerular filtration rate\n* The surgery must require general anesthesia with endotracheal intubation and neuromuscular blockade\n\nExclusion Criteria:\n\n* Any patient under the age of 18\n* Any patient over the age of 80\n* Any patient with end stage renal disease\n* Any patient requiring dialysis\n* Patients presenting for Renal Transplantation\n* Pregnant Female\n* Any patient in the correctional system\n* Urgent or Emergent procedure\n* The surgery requires intubation post-operatively\n* Documented allergy to Rocuronium, Sugammadex, Cisatracurium or Neostigmine",{"count":450,"type":21},490,[452],"PHASE4","The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is\n\n\"The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex.\"",[455,456,457],"Post Operative Pulmonary Complications","Neuromuscular Blockade","General Anesthesia","2026-02-19",{"date":460,"type":35},"2026-02-23",{"date":462,"type":35},"2025-08-26",{"date":464,"type":21},"2027-08-26",{"name":41,"class":42},{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":326,"enrollmentInfo":474,"targetDuration":4,"studyType":22,"phases":476,"briefSummary":477,"conditions":478,"keywords":480,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":489,"locationsCount":43},"100623924","stimulation-of-external-carotid-artery-circulation-100623924","NCT07402954","Stimulation of External Carotid Artery Circulation","Feasibility and Safety of Endovascular Bipolar Stimulation of the Middle Meningeal Artery for Refractory Headaches (MMA-Stim)","MMA-Stim","Inclusion Criteria:\n\n* Age ≥18\n* Chronic migraine or status migrainosus, or craniofacial pain refractory to maximal medical therapy who are undergoing MMA IA lidocaine infusion.\n* Subject has provided informed consent.\n\nExclusion Criteria:\n\n* Known allergies to lidocaine\n* Seizure disorder, history of seizures, or increased seizure susceptibility\n* Intracranial vascular malformations or dural AVF\n* Hemodynamic instability, any condition where brief hemodynamic shifts may pose risk\n* Previous MMA intervention or craniotomy that could result in MMA occlusion\n* Any implanted electronic device (pacemaker, ICD, DBS, VNS, cochlear implant, spinal cord stimulator)\n* Significant cardiovascular disease (unstable angina, severe arrhythmias, recent MI)\n* Severe autonomic dysfunction\n* Active systemic infection\n* Vulnerable populations (i.e. pregnant individuals, children, prisoners, individuals lacking decision-making capacity, persons with cognitive impairment, those unable to provide informed consent)",{"count":475,"type":21},12,[56],"This study is testing a new approach to help people with migraine headaches. Researchers want to find out if using electrical stimulation to affect blood flow in the external carotid artery is safe and practical for helping control headaches.\n\nThe goal of the study is to determine whether this approach could improve headache symptoms and overall outcomes for people with migraines.",[479],"Migraine",[479,481,482],"External carotid artery circulation","Bipolar Stimulation","2026-02-18",{"date":485,"type":35},"2026-02-20",{"date":487,"type":35},"2026-01-16",{"date":115,"type":21},{"name":41,"class":42},{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":95,"sex":150,"minAge":18,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":22,"phases":500,"briefSummary":502,"conditions":503,"keywords":505,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":516,"locationsCount":43},"100582544","early-phase-1-leveraging-video-logs-as-a-bridge-to-pre-exposure-prophylaxis-prep-with-tailored-messaging-to-black-women-and-their-healthcare-providers-in-texas-100582544","NCT06864689","Leveraging Video Logs as a Bridge to Pre-exposure Prophylaxis (PrEP) With Tailored Messaging to Black Women and Their Healthcare Providers in Texas.","PrEP","Selection criteria for participation in pilot RCT.\n\nEligible participants in the category for Black Women (BW) must:\n\n1. be a woman\n2. be 18 years of age\n3. have been sexually active with a man within the past 6 months\n4. be fluent in English\n5. have a phone or internet access\n\nEligible participants (i.e. PrEP-eligible BW) must not:\n\n1. be unable to provide informed consent\u002Fassent for participation (i.e., have severe cognitive impairment hat would interfere with their ability to consent or understand study procedures)\n2. have psychological distress that would prohibit them from participating in the study\n3. be unable or unwilling to meet study requirements\n4. be ineligible for PrEP\n5. received a prescription for PrEP within 12 months6)be unable to fill out the evaluation independently\n\nEligible participants in the HCP category must:\n\n1. be a credentialed HCP in Texas with privileges to prescribe and\u002For refer PrEP\n2. BW must be a part of their patient pool at the clinical setting where they practice clinically\n3. be fluent in English\n4. have a phone or internet access\n5. Live and\u002For practice medicine within a 60-mile radius of Houston\u002FHarris County\n\nEligible HCP must not:\n\n1. be unable to provide informed consent for participation (e.g. have severe cognitive impairment that would interfere with their ability to consent, or ability to understand study procedures\n2. have psychological distress that would prohibit them from participating in the study\n3. be unable or unwilling to meet study requirements\n4. be unwilling to offer PrEP to BW patients\n5. have prescribed or referred PrEP to BW within the last 12 months","99 Years",{"count":499,"type":21},78,[501],"EARLY_PHASE1","The primary objective of this R34 proposal is to increase willingness for PrEP initiation and PrEP initiation among Black Women (BW) and increase willingness to prescribe\u002Frefer pre-exposure prophylaxis (PrEP) to CBW among healthcare providers (HCPs) in Houston\u002FHarris County, a high priority Ending the HIV Epidemic (EHE) jurisdiction.",[504],"HIV Prevention",[506,507,495,508,509],"Minoritized population","Video logs","Health communication","Behavioral intervention","2026-02-11",{"date":512,"type":35},"2026-02-17",{"date":514,"type":21},"2026-09",{"date":441,"type":21},{"name":41,"class":42},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":95,"sex":17,"minAge":523,"maxAge":18,"enrollmentInfo":524,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":526,"conditions":527,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":43},"100369816","identification-of-neuromusculoskeletal-variables-associated-with-injury-risk-and-performance-in-high-school-athletes-100369816","NCT04095260","Identification of Neuromusculoskeletal Variables Associated With Injury Risk and Performance in High School Athletes.","Inclusion Criteria:\n\n* athletes who have completed a pre-participation sports physical\n* are enrolled in a sports elective or a member of a sports team\n* have volunteered to participate in the study providing both verbal and written consent.\n\nExclusion Criteria:\n\n* athletes who have not submitted a pre-participation sports physical to the high school training staff\n* student athletes who are currently suffering from an acute neuromusculoskeletal injury with restrictions on athletic participation\n* an athlete who has undergone surgery within a 3 month period of the program start date\n* an athlete who presents with a cardiovascular condition that would exclude exercise participation (systolic BP \\> 180, diastolic BP \\> 100)\n* an athletes who are currently pregnant.","14 Years",{"count":525,"type":21},250,"The purpose of this study is to complete a neuromuscular performance assessment of high school athletes who are participating in school based pre-season strength and performance training program. The performance assessment will screen for existing muscle imbalances and strength deficits known to increase risk for sports injury, and provide a baseline performance measurement. Athletes will be measured before the start of the program and then again at the end of the pre-season training period to measure changes in motor coordination, muscle strength, and performance and injury risk category. Internal and external training load will be measured weekly during the training program to track intensity of the training program. In addition to the pre and post measurements, sports injury occurrence and time away from sports participation will be tracked throughout the sport season\u002Fschool year to evaluate training program outcomes and accuracy of risk assessment.",[528],"Athletic Injuries","2026-02-05",{"date":531,"type":35},"2026-02-10",{"date":533,"type":21},"2028-08-01",{"date":535,"type":21},"2029-09-30",{"name":41,"class":42},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":326,"enrollmentInfo":544,"targetDuration":4,"studyType":22,"phases":546,"briefSummary":547,"conditions":548,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":559,"locationsCount":43},"100615554","phase-2-infusion-of-lidocaine-and-steroids-in-middle-meningeal-artery-for-pain-in-subarachnoid-hemorrhage-100615554","NCT07294118","Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage","Endovascular Infusion of Lidocaine and Steroids in the Middle Meningeal Artery for Pain Management in Spontaneous Subarachnoid Hemorrhage Patients","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosed with aneurysmal SAH, Hunt and Hess Grades 1-2.\n* Consent to study procedures and follow-up evaluations.\n\nExclusion Criteria:\n\n* Known allergies to lidocaine or steroids.\n* Arteriovenous malformations.\n* Dural Arteriovenous Fistulas.\n* Other significant intracranial pathologies.\n* Hemodynamic instability preventing safe intervention.\n* Previous MMA interventions.\n* Previous craniotomies or need for craniotomy.\n* Need for external ventricular drain.",{"count":545,"type":21},15,[155],"The goal of this clinical trial is to learn if an infusion of lidocaine, with or without steroids, into the middle meningeal artery (MMA) helps relieve severe headaches in patients with spontaneous subarachnoid hemorrhage (SAH). It will also study the safety of this treatment.",[549,550,551,552],"Subarachnoid Hemorrhage, Aneurysmal","Headache","Opiate Dependence","Opioid Use","2026-01-07",{"date":555,"type":35},"2026-01-09",{"date":557,"type":35},"2026-01-02",{"date":115,"type":21},{"name":41,"class":42},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":22,"phases":570,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":43},"100522269","promoting-intergenerational-health-in-rural-kentuckians-with-diabetes-pihrkd-100522269","NCT06080425","Promoting Intergenerational Health in Rural Kentuckians With Diabetes (PIHRK'D)","Addressing Intergenerational Obesity and Promoting Healthy Eating and Physical Activity Among Individuals [PIHRK'D] Living With Diabetes in Rural Kentucky","PIHRK'D","Inclusion Criteria:\n\n* must be diagnosed with type 2 diabetes\n* must be from rural Kentucky\n* must be living in rural Kentucky for at least 1 year\n\nExclusion Criteria:\n\n* potential participants without consent",{"count":569,"type":21},75,[56],"The goal of this feasibility study is to use family units as support to promote nutrition and physical activity of individuals with type 2 diabetes. The main question it aims to answer is:\n\n• How does the family structure impact the health of its members living with type 2 diabetes?\n\nParticipants will be asked to;\n\n* Tell us about their access to food sources and places in the community to engage in physical activity.\n* A nutrition and physical activity plan will be developed for participants and their families to use for 6 months.",[59],{"date":555,"type":35},{"date":575,"type":35},"2023-09-01",{"date":577,"type":21},"2026-05-31",{"name":41,"class":42},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":95,"sex":150,"minAge":18,"maxAge":587,"enrollmentInfo":588,"targetDuration":4,"studyType":22,"phases":590,"briefSummary":591,"conditions":592,"keywords":596,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":43},"100546482","thrive-well-cancer-fdtnexercisecreatine-supplementation-100546482","NCT06395506","THRIVE Well Cancer FDTN\u002FExercise_Creatine Supplementation","An Open-label Randomized Trial of Exercise ± Creatine Supplementation to Augment the Adaptations of Exercise Training in Cancer Survivors","THRIVE","Inclusion criteria (Breast Cancer Group)\n\n* Age 18-75 years of age\n* Diagnosis of breast cancer requiring chemotherapy\n* Recent (within 6 months) completion of chemotherapy\n* Willing to attend 3 virtual-based exercise sessions per week\n* Able to take oral medications\n* Participant is willing and able to provide consent to participating in the study\n* Serum creatinine ≤ 1.5 x ULN or Estimated glomerular filtration rate (eGFR) ≥30 mL\u002Fmin\u002F1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation.\n\nExclusion criteria (Breast Cancer Group)\n\n* Physical indications where performing exercise may be limited and\u002For contraindicated\n* Poorly controlled hypertension (blood pressure \\> 160\u002F95mmHg)\n* Current tobacco use (within 6 months)\n* Anabolic steroids use\n* Pitting edema greater than 2+\n* Currently undergoing chemotherapy treatment for cancer\n* History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation)\n* Pregnant or plan to become pregnant during the study\n* Recent (within one month) or anticipated treatment with corticosteroids (except for short term use during the time of chemotherapy), or other appetite stimulants\n* Serum creatinine \\> 1.5 x ULN or Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation\n* Currently taking creatine supplements\n* Lack of availability to a smartphone and\u002For internet\n\nInclusion Criteria (Healthy Age-matched Control Group)\n\n* Age 18-75 years of age\n* Have never been diagnosed with cancer\n* Willing to provide consent to participate in this study\n\nExclusion Criteria (Healthy Age-matched Control Group)\n\n* Physical indications where performing exercise may be limited and\u002For contraindicated\n* Poorly controlled hypertension (blood pressure \\> 160\u002F95mmHg)\n* Current tobacco use (within 6 months)\n* Anabolic steroids use\n* Pitting edema greater than 2+\n* History of cancer diagnosis\n* History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation)\n* Pregnant or currently taking prescribed medication to prepare for pregnancy (i.e.\n\nhormonal therapy for IVF)\n\n* Recent (within one month) treatment with corticosteroids\n* Recent (within one month) use of appetite stimulants or appetite suppressants\n* Serum creatinine \\> 1.5 x ULN or Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation\n* Diagnosed Bipolar Disorder or MDQ score indicative of bipolar disorder or Neurological disorders\n* Uncontrolled diabetes (A1c of 6.5% or higher)\n* Currently taking creatine supplements\n* Lack of availability to a smartphone and\u002For internet","75 Years",{"count":589,"type":21},60,[56],"The study's purpose is to evaluate whether creatine supplementation can help breast cancer survivors respond quicker to exercise by improving strength, endurance, and body composition. We are seeking to compare information collected from healthy woman of the same age who have never had breast cancer to those participants who have had breast cancer and undergone chemotherapy treatment.",[593,594,595],"Breast Cancer","Breast Cancer Female","Muscle Weakness",[593,594,597,598],"Exercise","Creatine Supplement","2025-12-17",{"date":601,"type":35},"2025-12-24",{"date":603,"type":35},"2024-10-29",{"date":605,"type":21},"2028-05-31",{"name":41,"class":42},{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":95,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":22,"phases":615,"briefSummary":616,"conditions":617,"keywords":619,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":43},"100562773","the-gut-brain-axis-during-neurorehabilitation-prebiotic-treatment-to-alter-the-gut-microbiome-and-neurologic-symptoms-100562773","NCT06607523","The Gut-Brain Axis During Neurorehabilitation; Prebiotic Treatment to Alter the Gut Microbiome and Neurologic Symptoms","Brain Injury Patients\n\nInclusion\n\n* Ages 18 and above\n* Admitted to Moody Neurorehabilitation Institute for care\n* Less than 6 months post-injury\n* English speaking\n* Must be able to eat and drink by mouth\n* Willing and able to comply with study procedures\n* Willing and able to provide consent (with LAR if needed)\n\nExclusion\n\n* Significant heart, liver, kidney, blood or respiratory disease\n* HIV, Hepatitis B or Hepatitis C\n* Pregnancy or becoming pregnant during the study\n* History of inflammatory bowel disease\n* History of celiac disease\n* Active diverticular disease\n* Known allergy to study agent\n* Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation\n\nCommunity Control Subjects\n\nInclusion\n\n* Ages 18 and above\n* Have a family member who is admitted to Moody Neurorehabilitation Institute for care OR is working at Moody Neurorehabilitation Institute\n* English speaking\n* Willing and able to comply with study procedures\n* Willing and able to provide consent\n* FACs score ≤ 50\n\nExclusion\n\n* Trauma to head in last 6 months\n* Stroke in last 6 months\n* Significant heart, liver, kidney, blood or respiratory disease\n* HIV, Hepatitis B or Hepatitis C\n* Pregnancy or becoming pregnant during the study\n* History of inflammatory bowel disease\n* History of celiac disease\n* Active diverticular disease\n* Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation",{"count":614,"type":21},130,[56],"The aim of this study is to characterize the microbiome of patients undergoing post-acute residential neurorehabilitation compared to community controls and to determine if a dietary fiber, Inulin, can create a shift in the microbiome leading to changes in fatigue and cognition.",[618],"Brain Injuries",[620,621,161,622],"Brain Injury","Neurorehabilitation","Cognition","2025-12-12",{"date":625,"type":35},"2025-12-19",{"date":627,"type":35},"2025-03-06",{"date":629,"type":21},"2028-10-01",{"name":41,"class":42},""]